omalizumab

omalizumab (OMLYCLO) is an FDA-listed pharmaceutical active ingredient. Associated with Novartis Pharmaceuticals. Current US regulatory status: approved.

OMLYCLO is a marketed brand name for omalizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.

omalizumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.